Capricor reports Q4 net loss $0.8M; Phase 3 DMD trial on track for top-line data Q4 2024

CAPRICOR THERAPEUTICS, INC.

2023-FY EPS reported -$0.83 revenue$25,178,066

Q4 2023 net loss $0.8M ($0.02/share) vs $7.7M ($0.31) in Q4 2022; revenue $12.1M from Nippon Shinyaku agreement.
Cash $39.5M at Dec 31, 2023; $10M milestone payment from Nippon Shinyaku received Jan 2024.
Enrollment complete in Cohort A of Phase 3 HOPE-3 trial for CAP-1002 in DMD; positive interim futility analysis.
Cohort B enrollment underway, expected to complete Q2 2024; top-line data from Cohort A expected Q4 2024.
Selected for Project NextGen; NIAID to fund Phase 1 trial of StealthX exosome-based COVID-19 vaccine in late 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CAPRICOR THERAPEUTICS, INC. reported financial results for the fourth quarter and full year ended December 31, 2023.

Period: the fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 29, 2024, Capricor Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter and full year ended December 31, 2023.

View on SEC.gov

171 earnings releases filed in the last 30 days. Browse all earnings releases →

CAPRICOR THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001558370-24-002183

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.